Current ENABLE-2 programmes

ENABLE-2 is currently supporting five promising programmes in the pursuit of new antibiotics: One from the University of Strathclyde, one resident at Leiden University and Queen’s University Belfast, one each from biotech companies QureTech Bio AB and Thioredoxin Systems AB, and one programme from Uppsala University​.

ENABLE-2 projekt

PROGRAMME BamA Inhibitors

Novel antibiotics that hit a new target against Gram-negative bacteria
Resident at Justus Liebig University Giessen and Fraunhofer IME, Giessen

Till F. Schäberle, PhD, Principal Investigator

Till F. Schäberle, PhD, Principal Investigator
Justus Liebig University Giessen


A new class of antibacterial compounds against gram-positive bacteria & a well-developed chemistry platform to improve these new compounds.
Resident at  QureTech Bio AB, Umeå

​Fredrik Almqvist, Research DirectorFredrik Almqvist, Research Director
QureTech Bio AB

Helen Fält, CEOHelén Fält, CEO
QureTech Bio AB

PROGRAMME Strathclyde Minor Groove Binders

An anti-infective drug discovery programme with a novel mechanism of action resilient to target-based resistance.
Resident at Department of Pure and Applied Chemistry, University of Strathclyde

Fraser J.Scott, Dr, Senior lecturer Fraser J.Scott, Dr, Senior lecturer 
University of Strathclyde


A novel target with no preexisting resistance and a new compound class showing very good efficacy in animal models.
Resident at  Drug Design and DiscoveryDep of Medicinal Chemistry & Dep of Medical Biochemistry and Microbiology, Uppsala University

Diarmaid Hughes, ProfessorDiarmaid Hughes, Professor
Uppsala University

Anders KarlenAnders Karlén, Professor
Uppsala University


A novel class of antibiotic active against multidrug-resistant gram-positive as well as gram-negative bacteria.
Resident at  Thioredoxin Systems AB, Solna

Elias ArnérElias Arnér, MD PhD, Board Member, Scientific Advisor
Thioredoxin Systems AB
+46 70 556 96 94,

Mohamad TakwaMohamad Takwa, PhD, Board Member, CEO
Thioredoxin Systems AB
+46 72-322 22 21,

PROGRAMME Ornicidine

A novel class of anti-bacterial agents active against multi drug-resistant Gram-negative bacteria.
Resident at Leiden University and Queen’s University Belfast

Nathaniel Martin, Professor LeidenNathaniel Martin, Professor
Leiden University

Stephen Cochrane, Dr.Stephen Cochrane, Dr.
Queen’s University Belfast

What ENABLE-2 can do for you

Apply to join


Marie OlliverMarie Olliver, PhD, Alliance Manager
Uppsala University

Last modified: 2023-09-18